Featured Editorial

  1. Targeted Delivery – A Holy Grail For CRISPR Gene Editing 2/26/2026

    Precise CRISPR delivery remains the bottleneck to safer, more potent gene editing. Advances in LNP design, targeting strategies, and extrahepatic delivery are redefining what’s possible in vivo.

  2. The Hidden Physics Of RNA-LNPs: Tuning RNA Encapsulation For Potency And Safety 2/25/2026

    Why LNPs that look identical behave differently in cells. This piece reveals how mixing physics and payload uniformity shape RNA potency, safety, dosing, and manufacturability—beyond size alone.

  3. Benchmarking RNA Delivery Performance: Toward Standardized Metrics For Translational Success 2/24/2026

    As RNA pipelines mature, delivery success demands shared benchmarks. This article proposes standardized, stage-specific metrics to compare platforms, guide optimization, and strengthen regulatory confidence.

  4. 2026 RNA Investment Landscape: Recent Deals, IPOs, And Venture Trends 2/22/2026

    As RNA investing matures, capital is flowing toward delivery, durability, and regulatory credibility. This column breaks down the deals, IPO signals, and venture theses shaping RNA’s 2026 winners—and why.

  5. Overcoming Lung Tumor Barriers: Nanoparticle Delivery Strategies For Pulmonary Cancers 2/20/2026

    Solid lung tumors have a complex tumor microenvironment that creates barriers to drug delivery. Nanoparticle therapies can overcome these challenges.

  6. Advances In Endometrial-Targeted Drug Delivery In Women's Health 2/19/2026

    Johns Hopkins investigators discuss gaps in women’s health research and how their work addresses endometrial dysfunction and infertility through precision nanomedicine.

  7. The Monster Under The Bed: Defining Potency in the mRNA Space 2/13/2026

    During the CASSS mRNA Symposium last spring, a seemingly simple, straightforward question was raised: How are we defining and measuring our product’s potency? But as we already know, this is far from a straightforward question — and, dear reader, based on the resulting discussion amongst regulators and panel members, it became clear we have a lot of different definitions on what potency even is in the mRNA space.

  8. RNA Delivery Technologies: Industrial Applications And Emerging Innovations 2/10/2026

    RNA delivery is moving from breakthrough to backbone. This review examines how LNPs and emerging carriers are reshaping scalability, targeting, manufacturing, and real-world deployment of RNA therapeutics.

  9. Innovations In The Oligonucleotide Supply Chain: Regulatory Considerations For Materials, Manufacturing, And Lifecycle Control 1/30/2026

    Oligonucleotide therapeutics have rapidly advanced into late-stage and commercial development, shifting regulatory focus toward the maturity of manufacturing and supply chain control rather than therapeutic novelty. Regulatory success now depends on how effectively sponsors translate innovative chemistries into well-characterized, scalable, and sustainable materials and processes.

  10. The mRNA Supply Chain Revolution: Materials, Methods, And Momentum 1/30/2026

    mRNA innovation now hinges as much on manufacturing materials as on molecular design, with novel inputs shaping performance, cost, and scalability. As these less-mature materials move rapidly into production, strategic material selection and supplier alignment are becoming critical to manufacturing resilience and long-term success.